A practical reference on peptide research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Surgery === In severe cases of AS, surgery can be an option in the form of joint replacements, particularly in the knees and hips. Surgical correction is also possible for those with severe flexion deformities (severe downward curvature) of the spine, particularly in the neck, although this procedure is considered very risky. In addition, AS can have some manifestations that make anesthesia more complex. Changes in the upper airway can lead to difficulties in intubating the airway, spinal and epidural anesthesia may be difficult owing to calcification of ligaments, and a small number of people have aortic insufficiency. The stiffness of the thoracic ribs results in ventilation being mainly diaphragm-driven, so there may also be a decrease in pulmonary function.
=== Financial considerations === Breastfeeding is less costly than alternatives, but the mother generally must eat more food than would otherwise be necessary. In the US, the extra money spent on food (about US $18 each week) is usually about half the cost of infant formula. According to the CDC, breastfeeding mothers need an extra 450 to 500 calories per day compared to their pre-pregnancy caloric intake. Breastfeeding reduces health care costs and the cost of caring for sick babies. Parents of breastfed babies are less likely to miss work and lose income because their babies are sick. Looking at three of the most common infant illnesses, lower respiratory tract illnesses, otitis media, and gastrointestinal illness, one study compared infants who had been exclusively breastfed for at least three months to those who had not. It found that in the first year of life, there were 2033 excess office visits, 212 excess days of hospitalization, and 609 excess prescriptions for these three illnesses per 1000 never-breastfed infants compared with 1000 infants exclusively breastfed for at least 3 months. However, in a study of over 140,000 newborns in the first month of life, exclusively breastfed newborns had higher hospital readmission rates than those exclusively formula fed, and those exclusively breastfed also had more neonatal outpatient visits compared to those exclusively formula fed.
Wenger's arrival at Arsenal was greeted with perplexity by some of the club's players, supporters and the local media. Although he was touted as a future technical director of The Football Association (FA), he was relatively unknown in English football. Glenn Moore's report in The Independent, dated 24 September 1996, highlighted the mood: "It is a measure of the insularity of the English game that when Arsène Wenger's name emerged as Arsenal's favoured candidate for their vacant manager's job many supporters were asking: 'Arsène who?'" Unlike his predecessors, Wenger was given control over transfers, contracts and training sessions, and the Arsenal board chose not to meddle in team affairs. One of his first acts as manager was to assure the experienced players they had a future at the club, but he noted the squad was "a bit tight," and needed competition for places. Wenger adopted a hands-on approach to training sessions which energised the squad, and made steps to change the drinking culture that afflicted Arsenal. Although he initially allowed players to have a pint of beer, they were forbidden to drink on days off and in the players' lounge. He later banned his players from casually drinking together. Wenger also promoted pasta as the pre-match dish, encouraged boiled chicken instead of red meat and discouraged junk food. Players received optional vitamin injections and Creatine, which reduced fatigue and improved their stamina.
relationship "a defining partnership of the 21st century", he also announced the removal of export control restrictions on several Indian companies, and concluded trade deals worth $10 billion, which are expected to create and/or support 50,000 jobs in the US.
Sources: en.wikipedia.org
Illicit diversion of pseudoephedrine in Australia has caused significant changes to the way the products are regulated. As of 2006, all products containing pseudoephedrine have been rescheduled as either "Pharmacist Only Medicines" (Schedule 3) or "Prescription Only Medicines" (Schedule 4), depending on the amount of pseudoephedrine in the product. A Pharmacist Only Medicine may only be sold to the public if a pharmacist is directly involved in the transaction. These medicines must be kept behind the counter, away from public access. Pharmacists are also encouraged (and in some states required) to log purchases with the online database Project STOP. As a result, some pharmacies no longer stock Sudafed, the common brand of pseudoephedrine cold/sinus tablets, opting instead to sell Sudafed PE, a phenylephrine product that has not been proven effective in clinical trials.
== Bibliography == Bagnall, K. W. (1962) [1962]. "The Chemistry of Polonium". Advances in Inorganic Chemistry and Radiochemistry. Vol. 4. New York: Academic Press. pp. 197–226. doi:10.1016/S0065-2792(08)60268-X. ISBN 978-0-12-023604-6. Retrieved 14 June 2012. {{cite book}}: ISBN / Date incompatibility (help) Greenwood, Norman N.; Earnshaw, Alan (1997). Chemistry of the Elements (2nd ed.). Butterworth–Heinemann. ISBN 978-0080379418.
=== Headache Disorders === Both isoforms of PACAP (PACAP-38 and PACAP-27) have been implicated in migraine pathogenesis. A Danish research group led by Dr. Messoud Ashina found that intravenous infusion of PACAP-38 induced migraine attacks in 58% of people with migraine, whilst the corresponding migraine induction rate was 55% for PACAP-27. Treatments with monoclonal antibodies have been investigated to target PACAP or its receptors for the treatment of primary headache disorders. In a phase 2, proof of concept study published in 2024, a monoclonal antibody treatment targeting PACAP (denoted Lu AG09222) reduced the number of migraine days in patients suffering from treatment-resistant migraines. Attempts to target its receptors have been less successful. Amgen's AMG-301, which targets the PAC1 receptor, failed to show greater efficacy than placebo in phase II trials.
Sources: en.wikipedia.org
He also invited Xi and his wife, Peng Liyuan, to visit the White House on 24 September 2026. The table arrangement and menu of the state banquet that night were circulated online afterward. Compared to Trump's last visit to China, the main table sits fewer people. The foods featured both Chinese culinary traditions and American elements. It included cold hors d'oeuvre dishes, main dishes such as golden lobster soup, crispy beef, Peking duck, salmon with mustard sauce, bean soup with fresh vegetables, and after mains including pan-fried buns with ice flowers, conch pastry, tiramisu, fruit, ice cream, coffee, tea, as well as Great Wall Chief Winemaker's Selected Cabernet Sauvignon 2009 from Hebei, China, and Changyu Reserve Chardonnay 2016 from Beijing, China. It was also rumored that the People's Liberation Army Military Band played 6 Chinese songs and 6 American songs during the state banquet. The Chinese songs included "Butterfly Lovers" and "Ru Yuan" sung by Faye Wong, while the last song played was Trump's campaign song "Y.M.C.A."
365–9, doi:10.1016/0003-2697(87)90464-7, PMID 3555154 Sinohara, H (1986), "[Rudolf Schoenheimer: a biographical essay]", Seikagaku, vol. 58, no. 12 (published Dec 1986), pp. 1449–70, PMID 3553368 Goldstein, J L (1986), "On the origin and prevention of PAIDS (Paralyzed Academic Investigator's Disease Syndrome)", J. Clin. Invest., vol. 78, no. 3 (published Sep 1986), pp. 848–54, doi:10.1172/JCI112652, PMC 423687, PMID 3528221 Stetten, D (1982), "Rudi", Perspect. Biol. Med., vol. 25, no. 3, pp. 354–68, doi:10.1353/pbm.1982.0056, PMID 6763679, S2CID 246283804
== Other animals == Degenerative disc disease can occur in other mammals besides humans. It is a common problem in several dog breeds, such as the Dachshund, and attempts to remove this disease from dog populations have led to several hybrid breeds, such as the Chiweenie.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.